Clinical bottom line
Acute severe alcoholic hepatitis (ASAH) remains a high-mortality condition requiring prompt recognition and multidisciplinary management. Current evidence supports corticosteroids as first-line therapy in selected patients without contraindications, but benefits are modest and not universal. Emerging approaches emphasize early risk stratification, supportive care optimization, and consideration of novel adjunctive therapies. Despite advances, treatment remains challenging with substantial unmet needs, warranting careful patient selection and ongoing clinical trials to refine therapeutic strategies.
What the evidence shows
Alcohol-associated liver disease guidelines from the American College of Gastroenterology (ACG) provide the most recent comprehensive recommendations for ASAH management (Jophlin et al., 2024). Corticosteroids, primarily prednisolone, remain the cornerstone for patients with severe disease defined by Maddrey’s discriminant function ≥32 or MELD scores indicating high short-term mortality. The 2018 ACG guideline (Singal et al., 2018) and the updated 2024 guideline (Jophlin et al., 2024) both emphasize corticosteroid use to improve short-term survival, although the magnitude of benefit is modest and not sustained long-term.
The Lille score is widely used to assess early response to corticosteroids after 7 days, guiding continuation or cessation to avoid unnecessary immunosuppression (Kasper et al., 2023). Patients with poor response have limited options and high mortality risk. Liver transplantation is an option for highly selected patients with ASAH refractory to medical therapy, but access and eligibility criteria remain restrictive.
Supportive care, including nutritional optimization, management of complications such as infections and acute kidney injury, and alcohol cessation support, is critical (Kasper et al., 2023). Recent literature highlights the role of multidisciplinary care teams to address the complex needs of these patients (Kalal Chetan et al., 2024).
Novel therapeutic approaches remain investigational. Trials of agents targeting inflammation, gut barrier dysfunction, and liver regeneration are ongoing but have not yet altered standard practice (Louvet et al., 2023). The role of granulocyte colony-stimulating factor (G-CSF) and other immunomodulatory therapies is under active study but requires validation.
Caveats and uncertainty
The evidence base for corticosteroids is largely derived from randomized controlled trials conducted decades ago, with some heterogeneity in patient populations and endpoints (Singal et al., 2018). The risk of infections and other corticosteroid-related adverse effects complicates treatment decisions. The optimal duration and dosing of corticosteroids remain debated.
There is no consensus on second-line therapies for non-responders, and liver transplantation criteria vary widely by center and region. Many novel therapies are still in early-phase trials or have conflicting results, limiting their current clinical applicability.
Furthermore, ASAH often occurs in patients with complex social and psychiatric comorbidities, which may affect adherence and outcomes but are underrepresented in clinical trials.
How this may change practice
Clinicians should continue to apply guideline-based corticosteroid therapy in carefully selected patients with ASAH, using validated scoring systems like Maddrey’s discriminant function and the Lille score to guide treatment initiation and continuation (Jophlin et al., 2024; Kasper et al., 2023). Early identification of non-responders is essential to avoid prolonged ineffective immunosuppression.
Multidisciplinary care models integrating hepatology, addiction medicine, nutrition, and psychosocial support may improve outcomes and should be prioritized (Kalal Chetan et al., 2024). Clinicians should remain vigilant for complications such as infections and renal dysfunction during corticosteroid therapy.
Emerging therapies and liver transplantation should be considered in specialized centers and clinical trial settings until more robust evidence becomes available (Louvet et al., 2023). Ongoing research may soon expand therapeutic options beyond corticosteroids, but current practice remains anchored in established guidelines.